P171 Can the turbu+™ adherence programme contribute to improved adherence to asthma controller treatment in italy?

Rumi, Gabriele; Braido, Fulvio; Canonica, Giorgio Walter; Foster, Juliet; Chavannes, Niels H.; Columbro, C.; Valenti, Giuseppe; Contiguglia, Rosario; Blas, Miguel A De; Kocks, Janwillem

doi:10.1136/thorax-2018-212555.329

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…152,153 Recent experience with Turbu+™ in Italy, for example, exemplified improved adherence. 154 Digital health developments have also shown great utility in the management of device errors, and are now able to provide detailed feedback on patients' device competence. 142 The SmartMist™ (Aradigm) and MDILog™ (Westmed Technologies) have both included sensing capabilities to facilitate the assessment of inhalation technique.…”

Section: New Technologiesmentioning

confidence: 99%

What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape

Lavorini

Janson

Braido

et al. 2019

Ther Adv Respir Dis

View full text Add to dashboard Cite

Inhaled therapies are the cornerstone of treatment in asthma and chronic obstructive pulmonary disease, and there are a multitude of devices available. There is, however, a distinct lack of evidence-based guidance for healthcare providers on how to choose an appropriate inhaler. This review aims to summarise recent updates on topics related to inhaler choice, and to offer practical considerations for healthcare providers regarding currently marketed devices. The importance of choosing the right inhaler for the right patient is discussed, and the relative merits of dry powder inhalers, pressurised metered dose inhalers, breath-actuated pressurised metered dose inhalers, spacers and soft mist inhalers are considered. Compiling the latest studies in the devices therapy area, this review focuses on the most common types of handling errors, as well as the comparative rates of incorrect inhalation technique between devices. The impact of device-specific handling errors on inhaler performance is also discussed, and the characteristics that can impair optimal drug delivery, such as inhalation flow rate, inhalation volume and particle size, are compared between devices. The impact of patient perceptions, behaviours and problems with inhalation technique is analysed, and the need for appropriate patient education is also highlighted. The continued development of technology in inhaler design and the need to standardise study assessment, endpoints and patient populations are identified as future research needs. The reviews of this paper are available via the supplemental material section.

show abstract

Section: New Technologiesmentioning

confidence: 99%

What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape

Lavorini

Janson

Braido

et al. 2019

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…A partial solution to these problems could be the use of intelligent devices, as already in use for inhaled therapies [33], or the use of dedicated apps for smartphones with dosing reminders and recording instruments for symptoms and quality of life [34]. The aforementioned are only speculative considerations that would need evidence-based data, for instance by direct comparisons between the two regimens (namely, autoinjection and doctor-supervised) or in the real-life setting, with a special attention to adherence and safety.…”

Section: Discussionmentioning

confidence: 99%

Biological agents for severe asthma: the evolution of the at-home self-injection approach

Lombardi

Bagnasco

Passalacqua

2020

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewNew biological agents, in addition to the well-established omalizumab, have been nowadays introduced into clinical practice for severe asthma. This suggested the possibility of an at-home self-administration, as currently happening for other biological agents for immune-mediated diseases. Recent findingsIn the very recent years, there were structured clinical trials investigating the self at home administrations of biologicals for severe asthma, showing with different principles, a possible advantage and convenience for the patient, and a socioeconomic saving.

show abstract

The measurement of adherence to inhaled corticosteroids in asthma using electronic monitoring devices: A systematic review and meta-analysis (Preprint)

Adejumo,

Chalitsios,

Shaw

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Electronic monitoring devices (EMDs) are increasingly considered the gold standard for quantifying inhaled corticosteroid (ICS) adherence in asthma. They are likely to play an important role in the future digitisation of self-management. However, there is a risk that early adoption without clarity of purpose could limit their utility. OBJECTIVE This review sought to ascertain an estimate of EMD-measured ICS adherence among people with asthma and understand the factors involved in their use. METHODS Searches were conducted in 2017 with updates in 2021 and 2023 across databases including Cochrane CENTRAL, MEDLINE, EMBASE, Web of Science, PsychINFO and IEEE Xplore. Studies were included if they used EMDs in adults with asthma and were randomised controlled trials (RCTs) or cohort studies. Summary data were extracted to inform narrative review and meta-analysis. The primary outcome was to derive a population estimate of ICS adherence. The study protocol is registered on the Prospero database (CRD42017057708). RESULTS Seventy-two RCTs and cohort studies were identified. RCT control groups were pooled with cohort studies for meta-analysis of the primary endpoint. Mean daily ICS adherence was 63.7% (95% Confidence Interval 59.2–68.2%, I2=98.9%). There was significant heterogeneity in device characteristics, study design, sample populations, definitions of adherence and use/choice of clinical outcome measures. CONCLUSIONS The findings suggest studies likely overestimate adherence compared to the general asthma population, even when objectively monitored. Minimum agreed standards for EMD outputs, accuracy, and agreed clinical outcome measures which are sensitive to digital interventions may be required for future research and clinical practice. CLINICALTRIAL N/A

show abstract

P171 Can the turbu+™ adherence programme contribute to improved adherence to asthma controller treatment in italy?

Cited by 3 publications

References 1 publication

What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape

What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape

Biological agents for severe asthma: the evolution of the at-home self-injection approach

The measurement of adherence to inhaled corticosteroids in asthma using electronic monitoring devices: A systematic review and meta-analysis (Preprint)

Contact Info

Product

Resources

About